Cyanidin-3-O-Glucoside Ameliorates Lipopolysaccharide-Induced Injury Both In Vivo and In Vitro Suppression of NF-κB and MAPK Pathways

• Published in: Inflammation Vol. 38; no. 4; pp. 1669 - 1682
• Main Authors: Ma, Ming-Ming, Li, Yan, Liu, Xiang-Yong, Zhu, Wei-Wei, Ren, Xiang, Kong, Gui-Qing, Huang, Xiao, Wang, Li-Peng, Luo, Li-Qing, Wang, Xiao-Zhi
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2015
• Subjects: Acute Lung Injury - chemically induced; Acute Lung Injury - drug therapy; Acute Lung Injury - metabolism; Animals; Anthocyanins - pharmacology; Anthocyanins - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cell Survival - drug effects; Cell Survival - physiology; Dose-Response Relationship, Drug; Glucosides - pharmacology; Glucosides - therapeutic use; Humans; Immunology; Internal Medicine; Lipopolysaccharides - toxicity; Male; MAP Kinase Signaling System - drug effects; MAP Kinase Signaling System - physiology; Mice; NF-kappa B - antagonists & inhibitors; NF-kappa B - metabolism; Pathology; Pharmacology/Toxicology; Rheumatology; nuclear factor-kappa B (NF-κB); mitogen-activated protein kinases (MAPKs); C3G; LPS; acute respiratory distress syndrome/acute lung injury (ARDS/ALI)
• ISSN: 0360-3997; 1573-2576
• DOI: 10.1007/s10753-015-0144-y

Cyanidin-3- O -glucoside (C3G), an anthocyanin belonging to the flavonoid family and commonly present in food and vegetables in human diet, has exhibited anti-inflammatory and anti-oxidant effects. This study aimed to investigate the protective ability of C3G against inflammatory and oxidative injuries, as well as to clarify the possible mechanism in lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs) in vitro and acute respiratory distress syndrome mouse model in vivo . HUVECs or male Kunming mice were pretreated with C3G 1 h before LPS stimulation. C3G significantly inhibited the production of pro-inflammatory cytokines (tumor necrosis factor-α, interleukin (IL) -6, and IL-1β) in cell supernatants and bronchoalveolar lavage fluid (BALF) as determined by enzyme-linked immunosorbent assay. Histopathologic examination with hematoxylin and eosinstaining showed that C3G pretreatment substantially suppressed inflammatory cell infiltration, alveolar wall thickening, and interstitial edemain lung tissues. C3G markedly prevented LPS-induced elevation of malondialdehyde and myeloperoxidase levels in lung tissue homogenates, wet to dry ratio of lung tissues, total cells, and inflammatory cells (neutrophils and macrophages) in BALF. Moreover, C3G reduced superoxide dismutase activity in the lung tissue homogenates. Western blot assay also showed that C3G pretreatment significantly suppressed LPS-induced activation of nuclear factor-kappaB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways by blocking the phosphorylation of inhibitor κB-α, NF-κB/P65, extracellular signal-regulated kinase, p38, and c-Jun NH2-terminal kinase in the lung tissues. In summary, C3G may ameliorate LPS-induced injury, which results from inflammation and oxidation, by inhibiting NF-κB and MAPK pathways and playing important anti-inflammatory and anti-oxidative roles.